Mem Inst Oswaldo Cruz, Rio de Janeiro, VOLUME 114 | NOVEMBER 2019
Original Article

Acinetobacter baumannii infections in Amazon Region driven by extensively drug resistant international clones, 2016-2018

Raquel Vosges Caldart1, Erica L Fonseca2,+, Fernanda Freitas2, Luiza Rocha3, Ana Carolina Vicente2

1Universidade Federal de Roraima, Boa Vista, RR, Brasil
2Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Genética Molecular de Microrganismos, Rio de Janeiro, RJ, Brasil
3Laboratório Central de Saúde Pública de Roraima, Boa Vista, RR, Brasil

DOI: 10.1590/0074-02760190232
27 views 6 downloads

BACKGROUND Acinetobacter baumannii is a leading cause of nosocomial infections. This species is characterised by the presence of pandemic lineages (International Clones) that present a broad antimicrobial resistance profile.

OBJECTIVE To perform the molecular epidemiology of carbapenem-resistant A. baumannii from a clinical setting in the Amazon Basin, and to characterise their antimicrobial resistance determinants.

METHODS The genetic relationship of carbapenem-resistant A. baumannii were assessed by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Class A, B and D β-lactamase genes were screened by polymerase chain reaction (PCR) and sequencing. The antimicrobial susceptibility profile was obtained by Disc-diffusion method and minimum inhibitory concentration (MIC) determination.

FINDINGS All carbapenem-resistant A. baumannii strains belonged to three international clones, IC-1, IC-5 and IC-6, the latter recently reported by the first time in Brazil. The major determinant of carbapenem resistance in IC-1 and IC-5 strains was blaOXA-23, associated with ISAba1 and ISAba3, respectively, while IC-6 harboured the blaOXA-72.

CONCLUSIONS The A. baumannii epidemiology in Brazilian Amazon Region was unknown. It was demonstrated that A. baumannii XDR international clones were responsible for nosocomial infections in Boa Vista during 2016-2018, revealing that the epidemiological scenario of A. baumannii infections in Amazon Region resembles those from the cosmopolitan regions worldwide.

01. Zarrilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents. 2013; 41: 11-19.
02. Rocha IV, Xavier DE, Almeida KRH, Oliveira SR, Leal NC. Multidrug-resistant Acinetobacter baumannii clones persist on hospital inanimate surfaces. Braz J Infect Dis. 2018; 22(5): 438-41.
03. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007; 5(12): 939-51.
04. Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One. 2010; 5(4): e10034.
05. Karah N, Sundsfjord A, Towner K, Samuelsen Ø. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. Drug Resist Updat. 2012; 15(4): 237-47.
06. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006; 12(9): 826-36.
07. Neves FC, Clemente WT, Lincopan N, Paião ID, Neves PR, Romanelli RM, et al. Clinical and microbiological characteristics of OXA-23- and OXA-143-producing Acinetobacter baumannii in ICU patients at a teaching hospital, Brazil. Braz J Infect Dis. 2016; 20(6): 556-63.
08. Rossi F, Girardello R, Cury AP, Di Gioia TSR, Almeida Jr JN, Duarte AJS. Emergence of colistin resistance in the largest university hospital complex of São Paulo, Brazil, over five years. Braz J Infect Dis. 2017; 21(1): 98-101.
09. Camargo CH, Tiba MR, Saes MR, Vasconcellos FM, Santos LF, Romero EC, et al. Population structure analysis of carbapenem-resistant Acinetobacter baumannii clinical isolates from Brazil reveals predominance of clonal complexes 1, 15, and 79. Antimicrob Agents Chemother. 2016; 60(4): 2545-7.
10. Chagas TP, Carvalho KR, Santos ICO, Carvalho-Assef AP, Asensi MD. Characterization of carbapenem-resistant Acinetobacter baumannii in Brazil (2008-2011): countrywide spread of OXA-23-producing clones (CC15 and CC79). Diagn Microbiol Infect Dis. 2014; 79(4): 468-72.
11. Pagano M, Nunes LS, Niada M, Barth AL, Martins AF. Comparative analysis of carbapenem-resistant Acinetobacter baumannii sequence types in southern Brazil: from the first outbreak (2007-2008) to the endemic period (2013-2014). Microb Drug Resist. 2019; 25(4): 538-42.
12. Meshkat Z, Amini Y, Sadeghian H, Salimizand H. ISAba1/blaOXA-23-like family is the predominant cause of carbapenem resistance in Acinetobacter baumannii and Acinetobacter nosocomialis in Iran. Infect Genet Evol. 2019; 71: 60-6.
13. Grosso F, Carvalho KR, Quinteira S, Ramos A, Carvalho-Assef AP, Asensi MD, et al. OXA-23-producing Acinetobacter baumannii: a new hotspot of diversity in Rio de Janeiro? J Antimicrob Chemother. 2011; 66(1): 62-5.
14. CLSI - Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing 22th informational supplement (M100-S27) 2017. Wayne: CLSI; 2017.
15. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18(3): 268-81.
16. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect. 2001; 7(2): 88-91.
17. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995; 33: 2233-9.
18. Bartual SG, Seifert H, Hippler C, Luzon MA, Wisplinghoff H, Rodríguez-Valera F. Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol. 2005; 43(9): 4382-90.
19. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward E, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006; 27: 351-3.
20. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010; 65(2): 233-8.
21. Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifer H. OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother. 2009; 53(12): 5035-8.
22. Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010; 65: 490-5.
23. Poirel L, Revathi G, Bernabeu S, Nordmann P. Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. Antimicrob Agents Chemother. 2011; 55(2): 934-6.
24. Nicoletti AG, Marcondes MFM, Martins WMBS, Almeida LGP, Nicolás MF, Vasconcelos ATR, et al. Characterization of BKC-1 class A carbapenemase from Klebsiella pneumoniae clinical isolates in Brazil. Antimicrob Agents Chemother. 2015; 59(9): 5159-64.
25. Corvec S, Poirel L, Naas T, Drugeon H, Nordmann P. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51: 1530-3.
26. Royer S, de Campos PA, Araújo BF, Ferreira ML, Gonçalves IR, Batistão DWDF, et al. Molecular characterization and clonal dynamics of nosocomial blaOXA-23 producing XDR Acinetobacter baumannii. PLoS One. 2018; 13(6): e0198643.
27. Tavares LCB, de Vasconcellos FM, de Sousa WV, Rocchetti TT, Mondelli AL, Ferreira AM, et al. Emergence and persistence of high-risk clones among MDR and XDR A. baumannii at a Brazilian teaching hospital. Front Microbiol. 2019; 9: 2898.
28. Levy-Blitchtein S, Roca I, Plasencia-Rebata S, Vicente-Taboada W, Velásquez-Pomar J, Muñoz L, et al. Emergence and spread of carbapenem-resistant Acinetobacter baumannii international clones II and III in Lima, Peru. Emerg Microbes Infect. 2018; 7(1): 119.
29. Fonseca ÉL, Caldart RV, Freitas FS, Morgado SM, Rocha LT, Santos RCD, et al. Emergence of XDR international clone IC-6 Acinetobacter baumannii carrying blaOXA-72 and blaCTX-M-115 in the Brazilian Amazon Region. J Glob Antimicrob Resist. 2019; S2213-7165(19): 30158-4 [Epub ahead of print].
30. Giannouli M, Cuccurullo S, Crivaro V, Di Popolo A, Bernardo M, Tomasone F, et al. Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a tertiary care hospital in Naples, Italy, shows the emergence of a novel epidemic clone. J Clin Microbiol. 2010; 48: 1223-30.
31. Fernández-Cuenca F, Rodríguez-Martínez JM, Gómez-Sánchez MC, Alba PD. Production of a plasmid-encoded OXA-72 β-lactamase associated with resistance to carbapenems in a clinical isolate Acinetobacter junii. Int J Antimicrob Agents. 2012; 39: 90-4.

Financial support: CNPq, Instituto Oswaldo Cruz (grant).
+ Corresponding author:
Received 04 July 2019
Accepted 06 November 2019

Citation: Caldart RV, Fonseca EL, Freitas F, Rocha L, Vicente AC. Acinetobacter baumannii infections in Amazon Region driven by extensively drug resistant international clones, 2016-2018. Mem Inst Oswaldo Cruz. 2019; 114: e190232.

Our Location

Memórias do Instituto Oswaldo Cruz

Av. Brasil 4365, Castelo Mourisco 
sala 201, Manguinhos, 21040-900 
Rio de Janeiro, RJ, Brazil

Tel.: +55-21-2562-1222

This email address is being protected from spambots. You need JavaScript enabled to view it.

Support Program

logo fiocruz logo governo
logo faperj logo cnpq marca capes